GuideMaker - About the company
GuideMaker is an unfunded company, founded in 2020. It operates as a Software to design CRISPR-Cas guide RNA pools in non-model genomes. GuideMaker has not raised any funding yet. The company has 850 active competitors, including 303 funded and 159 that have exited. Its top competitors include companies like Alnylam, Forge Biologics and Beam Therapeutics.
Company Details
Software to design CRISPR-Cas guide RNA pools in non-model genomes. This tool enables the rapid generation of guide sequences for gene targets across organisms using degenerate protospacer adjacent motifs and genomic files. The application utilizes graph-based algorithms to compare sequences and identify specific guide RNA candidates. It supports various Cas enzymes and accommodates different genomic data formats for experimental design. The software is available as a command-line tool, a containerized image, and a web application to facilitate functional genetic studies.
Key Metrics
Sign up to download GuideMaker's company profile
GuideMaker's funding and investors
GuideMaker has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
GuideMaker's Competitors and alternates
Top competitors of GuideMaker include Alnylam, Forge Biologics and Beam Therapeutics. Here is the list of Top 10 competitors of GuideMaker, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 81/100 | |
2nd |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 72/100 | |
3rd |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 72/100 | |
4th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
5th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 71/100 | |
6th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 69/100 | |
7th | Ionis 1989, United States, Public | Developer of RNA-targeted medicines for various diseases | - | 69/100 | |
8th | Seer 2017, San Francisco (United States), Public | Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | 68/100 | |
9th | Stoke Therapeutics 2014, Bedford (United States), Public | Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing | $131M | 68/100 | |
10th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of genome editing therapeutics using CRISPR and Cas9 technology | $85M | 68/100 | |
919th | GuideMaker 2020, Unfunded | Software to design CRISPR-Cas guide RNA pools in non-model genomes | - | - | 16/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on GuideMaker's competitors? Click here to see the top ones
GuideMaker's Investments and acquisitions
GuideMaker has made no investments or acquisitions yet.
Reports related to GuideMaker
Here is the latest report on GuideMaker's sector:
Are you a Founder ?
FAQs about GuideMaker
Explore our recently published companies
